Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Nonaspirin NSAIDs and contralateral breast cancer risk

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Change in mammographic density across birth cohorts of Dutch breast cancer screening participants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Vitamin D levels and Cancer Incidence in 217.244 individuals from Primary Health Care in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Human papillomavirus and p16 in squamous cell carcinoma and intraepithelial neoplasia of the vagina

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. A Comprehensive Gene-Environment Interaction Analysis in Ovarian Cancer using Genome-wide Significant Common Variants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Subtypes in BRCA-mutated breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Pattern of mortality after menopausal hormone therapy: long-term follow up in a population-based cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Laboratory studies suggest that inhibition of the cyclooxygenase (COX)-2 enzymes inhibits breast cancer development. We aimed to evaluate whether postdiagnosis use of COX-2 selective or other nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of contralateral breast cancer (CBC) among Danish breast cancer patients. From the clinical database of the Danish Breast Cancer Group, we identified 52,723 women diagnosed with breast cancer between 1996 and 2012. Data on nonaspirin NSAID use, CBC and potential confounding variables were obtained from nationwide registries. We defined postdiagnosis use (two or more prescriptions) as a time-varying covariate with a one-year lag. Cox proportional hazard regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for CBC associated with nonaspirin NSAID use. During a median follow-up of 4.8 years (interquartile range: 2.3-9 years), 1,444 patients were diagnosed with CBC. Overall, postdiagnosis use of nonaspirin NSAID was associated with an adjusted HR for CBC of 0.98 (95% CI: 0.87-1.11). The HRs did not vary substantially with duration or intensity of nonaspirin NSAID use. Moreover, similar associations were found for COX-2 selective (HR: 1.02; 95% CI: 0.85-1.23) and nonselective (HR: 0.96; 95% CI: 0.82-1.13) nonaspirin NSAIDs. In conclusion, our nationwide cohort study of breast cancer patients does not suggest a reduced risk of CBC with nonaspirin NSAID use regardless of the COX-2 selectivity.

OriginalsprogEngelsk
TidsskriftInternational Journal of Cancer
Vol/bind144
Udgave nummer6
Sider (fra-til)1243-50
ISSN0020-7136
DOI
StatusUdgivet - 2019

ID: 55905463